Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

NCT01838590 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: SOF
DRUG: RBV

Sponsor

Gilead Sciences